What a PAI inspection readiness checklist must cover in 2026
A PAI inspection readiness checklist has to be built around FDA’s four preapproval inspection objectives in Compliance Program 7346.832, revised on 29 June 2026 and implemented from 10 August 2026.[1] FDA’s integrated quality assessment team decides, on cumulative risk, whether a site is inspected at all and which objectives are covered.
- Objective 1Readiness for commercial manufacturing (sub-objectives 1a to 1e)
- Objective 2Conformance to application
- Objective 3Data integrity audit
- Objective 4Commitment to quality in pharmaceutical development
Objectives 1a, 1e, 2 and 3 are covered on every PAI; 1b, 1c and 1d are covered when risk factors apply; Objective 4 is covered on a site’s first PAI and then periodically.[1]
What changed in FDA’s pre-approval inspection program
Correction to the earlier version of this page. We previously described three PAI objectives (data integrity, facilities and process validation) and a 30-day 483 response window. Both were wrong. FDA’s program has four objectives, and FDA’s general policy allows 15 business days for a Form 483 response.[1][3]
Risk decides whether you are inspected
Within 60 calendar days of receiving an NDA or ANDA, FDA’s manufacturing assessment office either requests a PAI or enters a facility recommendation without one.[1] Inspection history, profile codes, product complexity and hazard signals drive that call.
Objective 1 is now split into 1a to 1e
Two sub-objectives are mandatory (capability and trends; feasibility of the commercial process). Three are risk-based (sampling and supplier qualification; contamination controls; release, change and reporting procedures).[1]
Alternative tools can replace a visit
A records request under section 704(a)(4), a remote interactive evaluation, or an inspection report from an MRA partner (EU, UK, Swissmedic) can be used in lieu of or in advance of a PAI.[1][4]
Biologics have their own program
PAIs and prelicense inspections (PLIs) for BLAs, including biosimilars, follow Compliance Program 7346.832M, issued 14 April 2026 and implemented from 14 May 2026.[2] Cell and gene therapies are CBER-regulated and fall outside both CDER programs.
Which PAI objectives will FDA likely cover at your site?
Answer three questions. The result maps your situation to the coverage rules in the program’s objective table.[1] It is indicative only: FDA’s assessment team decides, and its written input to the inspection lead can add or narrow coverage.
Choose one option in each row
Your result will list the objectives FDA’s program says to cover and the trigger behind each.
Based on CP 7346.832 (issued 29 Jun 2026), Part II.2.C.
USFDA PAI checklist, objective by objective
Each item is tagged FDA where it restates what the program tells investigators to examine,[1] or Practice where it is our recommendation from site readiness work, not an FDA requirement. Ticks are saved in this browser only.
1a Capabilities, changes, deviations, trends (every PAI)
1b Sampling, testing and supplier qualification (risk-based)
1c Facility and equipment contamination controls (risk-based)
1d Release, change, investigation and FDA reporting (risk-based)
1e Feasibility of the commercial process (every PAI)
Objective 2: conformance to application (every PAI)
Objective 3: data integrity audit (every PAI)
Objective 4: commitment to quality in development (first PAI, then periodic)
FDA cites Objective 4 gaps on a Form 483 only when they link to a CGMP violation under Objectives 1 to 3.[1]
Before and during the inspection
After the close-out
Need this checklist mapped to your own SOP numbers and CMC sections? Request an editable copy.
FDA pre-approval inspection timeline
- Application received
FDA forms an integrated quality assessment team and reviews each named facility’s status and risk.[1] Separately, it decides within 60 days whether an NDA can be filed. A refuse-to-file decision is a filing decision, not a PAI outcome.[7]
- PAI requested or waived within 60 calendar days
FDA’s manufacturing assessment office requests a PAI with a written justification, or enters a facility recommendation without one.[1]
- Notice to the site original NDA: 60+ days ahead
For original NDAs, FDA’s goal is to notify at least 60 days before the PAI and no later than mid-cycle. FDA can still inspect at any time, announced or not.[1] FDA said in May 2025 that it is expanding unannounced inspections at foreign plants.[6]
- Inspection and close-out concerns flagged within 2 business days
The inspection lead sends concerns, any Form 483 and an initial field recommendation to the program manager within 2 business days of closing.[1]
- Your Form 483 response 15 business days
FDA’s general policy allows 15 business days before it decides further action.[3] For a PAI, a response that arrives before the application action date can change the facility recommendation.[1]
- Approve or withhold within 20 business days of close
The facility recommendation is entered no later than 20 business days after the inspection closes and before the user-fee goal date.[1] If FDA will not approve the application, it issues a complete response letter.[8]
The 13 grounds FDA lists for a withhold recommendation
Part V of the program gives these as examples of significant issues.[1] Use them as your mock-PAI failure criteria.
- Significant data integrity problems, including misrepresented data on submission batches
- Serious CGMP concerns with a biobatch or pivotal clinical, exhibit or validation batch
- Significant differences between the pivotal or biobatch process and the exhibit-batch process
- Incomplete manufacturing and control instructions in the master production record, or no data behind them
- No capacity to manufacture the drug product or API
- Failure to meet application commitments, such as not performing the functions described
- Full-scale process performance qualification attempted and failed, with no appropriate changes made
- Where full-scale data are filed, no proof the product can be made reliably at scale or meet its CQAs
- Incomplete or unsuccessful analytical method validation or verification
- Equipment or processing parameters not clearly identified in biobatch, pivotal or exhibit records
- Significant stability failures that question the stability of the product or API
- Failing data or adverse findings not reported, without justification
- Delaying, denying, limiting or refusing an inspection
Not a withhold ground on its own: incomplete commercial-scale process validation at the time of the PAI. The product still cannot be distributed until validation gives a high degree of assurance.[1]
PAI vs routine GMP inspection vs PLI vs remote assessment
| Type | FDA program | Triggered by | What it examines | Outcome |
|---|---|---|---|---|
| Pre-approval inspection (PAI) | CP 7346.832[1] | A pending NDA or ANDA, when the risk assessment calls for it | The four objectives, for the application product | Approve or withhold recommendation on the application |
| Prelicense / pre-approval (biologics) | CP 7346.832M[2] | An original or supplemental BLA for a CDER-regulated biologic or biosimilar | Facility readiness for the licensed product | Supports the licensing decision |
| Surveillance (routine GMP) | CP 7356.002, cited in CP 7346.832[1] | CDER’s risk-based site selection, a for-cause need, or PAI findings that point to marketed products | Quality systems across marketed products | NAI, VAI or OAI classification; can lead to regulatory action |
| Remote regulatory assessment | Section 704(a)(4) request or voluntary remote interactive evaluation[4] | FDA’s choice, in lieu of or before a PAI | Records, livestreamed operations, screen sharing | Informs the decision, but is not an inspection under section 704(a)(1)[1] |
Scroll the table sideways to see all columns.
If systemic CGMP problems appear during a PAI, FDA can expand it into surveillance coverage of the site’s marketed products. A pattern of unreliable data can lead FDA to consider its Application Integrity Policy.[1] That is why the data-integrity groundwork in our ALCOA vs ALCOA+ comparison by regulator and 21 CFR Part 11 clause-by-clause guide belongs in PAI preparation, not after it.
For Indian sites filing ANDAs
Two things change the planning for a site in India. First, FDA announced on 6 May 2025 that it would expand unannounced inspections abroad, building on its pilot in India and China.[6] The 60-day notice goal for original NDAs does not apply to ANDAs, so readiness has to be continuous.[1]
Second, the same plant is now inside Revised Schedule M enforcement at home. The extended MSME compliance window closed on 31 December 2025, and a CDSCO directive of 7 November 2025 asked state regulators to plan inspections and report monthly, as reported by Business Standard.[9] A site that cannot show Schedule M compliance to its state inspector is unlikely to be ready for FDA’s Objective 1. Status checked 21 October 2026.
For method-related findings, see our guide to method validation under ICH Q2(R2); for the full surveillance picture, see the 10 most-cited Form 483 observations and a six-system audit checklist.
FAQ: FDA pre-approval inspection
A PAI is an FDA inspection of a facility named in a pending NDA or ANDA. It checks that the site can make the product as described in the application under CGMP, and that the data submitted are accurate and complete. It is governed by Compliance Program 7346.832, revised in June 2026.[1]
Readiness for commercial manufacturing, conformance to application, data integrity audit, and commitment to quality in pharmaceutical development. Readiness is split into sub-objectives 1a to 1e; 1a, 1e, 2 and 3 are covered on every PAI.[1]
No. FDA decides on cumulative risk, using the site’s inspection history, profile codes, product complexity and hazard signals. It can rely on a records request, a remote interactive evaluation or an MRA partner’s inspection report instead of, or before, an on-site PAI.[1]
A PAI is tied to one pending application and ends in an approve or withhold recommendation. A routine surveillance inspection under CP 7356.002 covers the quality systems behind marketed products and ends in an NAI, VAI or OAI classification. FDA can expand a PAI into surveillance if it finds systemic problems.[1]
Not by itself. FDA expects Stage 1 process design data at minimum and will not withhold solely because commercial-scale validation is incomplete. A full-scale qualification that was attempted and failed, with no appropriate changes, is a withhold ground.[1]
Start with the inspection your state regulator will run
For Indian plants preparing an ANDA, the quickest gap analysis covers Revised Schedule M first, then layers on the FDA objectives above. Our dashboard maps each Schedule M requirement to the evidence an inspector asks for.
Open the CDSCO Schedule M compliance dashboardRelated on Laafon
References
- U.S. Food and Drug Administration. Compliance Program 7346.832: Preapproval Inspections. Issued 29 Jun 2026; implementation date 10 Aug 2026. Silver Spring (MD): FDA; 2026. Available from: https://www.fda.gov/media/193382/download. Accessed Oct 2026.
- U.S. Food and Drug Administration. Compliance Program 7346.832M: Prelicense and Preapproval Inspections of CDER-Regulated Biological Product Manufacturers. Issued 14 Apr 2026; implementation date 14 May 2026. Silver Spring (MD): FDA; 2026. Available from: https://www.fda.gov/media/191983/download. Accessed Oct 2026.
- U.S. Food and Drug Administration. Review of Post-Inspection Responses. Fed Regist. 2009 Aug 11;74(153). Docket No. FDA-2009-N-0335. Available from: https://www.govinfo.gov/content/pkg/FR-2009-08-11/html/E9-19107.htm. Accessed Oct 2026.
- U.S. Food and Drug Administration. Conducting Remote Regulatory Assessments: Questions and Answers. Guidance for industry (final). Jun 2025. Docket No. FDA-2022-D-0810. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-remote-regulatory-assessments-questions-and-answers. Accessed Oct 2026.
- U.S. Food and Drug Administration. Data Integrity and Compliance With Drug CGMP: Questions and Answers. Guidance for industry. Dec 2018. Docket No. FDA-2018-D-3984. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers. Accessed Oct 2026.
- U.S. Food and Drug Administration. FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities [press release]. 6 May 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities. Accessed Oct 2026.
- Code of Federal Regulations. Title 21, Section 314.101: Filing an NDA and receiving an ANDA. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.101. Accessed Oct 2026.
- Code of Federal Regulations. Title 21, Section 314.110: Complete response letter to the applicant. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.110. Accessed Oct 2026.
- Business Standard. Pharma units likely to face action for Schedule M violations: experts. 8 Nov 2025 (secondary source reporting a CDSCO directive of 7 Nov 2025). Available from: https://www.business-standard.com/industry/news/cdsco-asks-state-units-to-start-inspections-under-schedule-m-norms-125110801170_1.html. Accessed Oct 2026.
This page is technical and educational information, not legal or regulatory advice for a specific application. FDA compliance programs, guidances and Indian statutory instruments are revised often; check the current version of each source before relying on it. Items marked Practice are the author’s recommendations, not FDA requirements.
